« Counting CRO's in China - One Upsmanship! | Main | FDA and USP to Hook Up on Monographs (& such) »
As very very recently reported in the Pharmalot blog, the FDA has just approved Dendreon's Provenge as the first vaccine for prostate cancer! After almost 3 years in the waiting in agency - the good news is out for Dendreon stockholders and share price has jumped 15%.
Posted By Bruce Lehr April 29th 2010.
| | |
TrackBack URL for this entry:
http://www.typepad.com/services/trackback/6a0120a77f675b970b0133ed0f2c64970b
Listed below are links to weblogs that reference Clarion Call - FDA Approves Dendreon Provenge!:
You can follow this conversation by subscribing to the comment feed for this post.
The comments to this entry are closed.
With regard to the pricing question posed in my post on April 16th (http://thebigredbiotechblog.typepad.com/the-big-red-biotech-blog/2010/04/when-are-the-prices-right-for-dendreons-provenge.html), Michael Schulman of Seeking Alpha suggests Dendreon management has blown it by not lowering price to encourage off label use to expand market. Novel idea - perhaps not from investment type.
http://seekingalpha.com/article/202032-dendreon-yes-it-got-fda-approval-but-here-s-what-it-did-wrong
Posted by: Bruce Lehr | 04/30/2010 at 07:28 PM
And from the WSJ http://online.wsj.com/article/SB10001424052748704302304575214302390884556.html?mod=rss_Health
Posted by: Bruce Lehr | 04/29/2010 at 02:31 PM
And more from Fierce Biotech....http://www.fiercebiotech.com/story/fda-approves-dendreons-breakthrough-cancer-vaccine-provenge/2010-04-29
Posted by: Bruce Lehr | 04/29/2010 at 02:22 PM
Much more detail from Luke Timmerman's article in Xconomy. http://www.xconomy.com/seattle/2010/04/29/dendreon-makes-history-fda-approves-first-active-immune-booster-to-fight-cancer/
Posted by: Bruce Lehr | 04/29/2010 at 01:11 PM